Seasonal allergic rhinitis affects up to one in five Quebec residents, with projections indicating that up to 50% of the population could experience allergies by 2050, largely driven by ragweed pollen, according to public health and medical authorities. To manage spring and summer symptoms such as nasal congestion and itchy eyes, medical guidelines direct patients toward modern treatments while warning against older therapies and specific depot corticosteroid injections.
First-Line Medical Treatments for Seasonal Allergies
For mild to moderate allergic rhinitis, medical authorities recommend second-generation H1 antihistamines as a primary option, according to regional clinical guidance. Drugs such as cetirizine, loratadine, fexofenadine, desloratadine, bilastine, and rupatadine block histamine to reduce sneezing, nasal discharge, and itching while causing significantly fewer sedative effects than older molecules. When nasal congestion becomes a daily barrier, international ARIA guidelines and the French Society of ENT (SFORL) recommend intranasal corticosteroids—including fluticasone, mometasone, budesonide, and triamcinolone sprays—used once daily to sustainably control inflammation. Additionally, health authorities highlight simple saline nasal rinses as an effective, non-medicated method to clear allergens and improve daily comfort.
Allergen Immunotherapy to Target Underlying Causes
When symptoms persist despite proper use of antihistamines and nasal sprays, or when patients develop associated allergic asthma, allergists recommend allergen immunotherapy to modify the disease course. The treatment exposes the immune system to very low, gradual doses of allergens—such as grass pollens, tree pollens like birch, or dust mites—to retrain immune tolerance over a standard three-year or three-season course. Patients can receive immunotherapy either via regular subcutaneous injections supervised in a clinical setting or through daily sublingual tablets and drops taken at home after an initial monitored dose, according to public health and medical data.
Treatments and Practices to Avoid
Medical authorities caution against outdated or high-risk interventions for routine hay fever, specifically targeting long-acting injectable corticosteroids such as triamcinolone acetonide depot, commonly known as Kenalog. According to health agency guidelines, these depot injections diffuse for four to six weeks, making it impossible to reverse adverse effects if a patient experiences metabolic disruptions, blood sugar spikes, or bone and immune weakening. Public health officials emphasize that injectable cortisone should be strictly reserved for acute allergic emergencies rather than seasonal rhinitis management. Similarly, first-generation antihistamines like diphenhydramine and promethazine are discouraged due to heavy sedation, impaired alertness, and anticholinergic risks, particularly among older adults. Healthcare providers also advise limiting nasal vasoconstrictor sprays and oral pseudoephedrine to short, multi-day windows under professional guidance rather than using them as long-term preventative care.
